An open-label, randomized, phase 3 trial of Nivolumab vs Investigator's choice chemotherapy as first-line therapy for stge IV or recurrent PD-L1+non-small cell lung cancer

Administered By

Awarded By

Contributors

Start/End

  • February 1, 2014 - November 30, 2021